Drugs / Pfizer-BioNTech COVID-19 mRNA vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07597070 Comparator | Sep 2026 → Mar 2035 expected | non-small cell lung carcinoma | University of Florida | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pfizer-BioNTech COVID-19 mRNA vaccine | “Participants will receive a Pfizer-BioNTech COVID-19 mRNA vaccine within 7 days before initiating their immune checkpoint inhibitor therapy.” NCT07597070 ↗ |
| Known as | Pfizer-BioNTech mRNA COVID-19 vaccine | “Biological: Pfizer-BioNTech mRNA COVID-19 vaccine” NCT07597070 ↗ |
| Modality | Messenger RNA (mRNA) | “Pfizer-BioNTech COVID-19 mRNA vaccine” NCT07597070 ↗ |